Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Nextmune in connection with its acquisition of I.C.F. S.r.l and D.R.N. S.r.l.
Mandate

Vinge advised Nextmune in connection with its acquisition of I.C.F. S.r.l and D.R.N. S.r.l.

October 08, 2020 Banking and Finance M&A

Vinge has advised Fidelio Capital and its portfolio company Nextmune, a leading science driven, global specialty pharmaceutical company dedicated to improving health for dogs, cats and horses, in connection with its acquisition of I.C.F. S.r.l and D.R.N. S.r.l.

Vinge’s team consisted of, among others, Jonas Bergström, Matthias Pannier, Maria Dahlin-Kolvik, Karl Klackenberg, Manne Bergström, Vilhelm Rondahl and Albert Wållgren, Josefine Lanker, Axel Jansson och Jolinn Uhlin.

Related

Vinge has advised Oncopeptides in connection with a directed share issue

 Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

 Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

 Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026